Edwards Lifesciences Corporation (NYSE:EW) – William Blair upped their Q4 2017 earnings estimates for Edwards Lifesciences in a note issued to investors on Friday. William Blair analyst M. Kaczor now anticipates that the medical research company will post earnings of $0.89 per share for the quarter, up from their prior forecast of $0.88. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Edwards Lifesciences’ Q1 2018 earnings at $0.98 EPS, Q2 2018 earnings at $1.13 EPS, Q3 2018 earnings at $1.01 EPS, Q4 2018 earnings at $1.09 EPS and FY2018 earnings at $4.16 EPS.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.02). Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The business had revenue of $821.50 million during the quarter, compared to the consensus estimate of $833.85 million. During the same period last year, the business posted $0.68 EPS. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis.

Other research analysts also recently issued research reports about the stock. Morgan Stanley decreased their price objective on shares of Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating for the company in a research report on Thursday, October 26th. Royal Bank Of Canada reissued a “buy” rating and issued a $130.00 price objective on shares of Edwards Lifesciences in a research report on Friday, September 1st. BMO Capital Markets restated a “buy” rating and set a $137.00 target price on shares of Edwards Lifesciences in a research note on Friday. Canaccord Genuity restated a “buy” rating and set a $155.00 target price on shares of Edwards Lifesciences in a research note on Sunday, October 8th. Finally, Barclays restated an “equal weight” rating and set a $120.00 target price on shares of Edwards Lifesciences in a research note on Saturday, September 30th. Six analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $126.43.

Edwards Lifesciences (EW) opened at $118.03 on Monday. Edwards Lifesciences has a 12-month low of $86.55 and a 12-month high of $121.45. The company has a market cap of $24,980.00, a PE ratio of 32.70, a PEG ratio of 2.11 and a beta of 0.51. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.49 and a quick ratio of 2.76.

A number of institutional investors and hedge funds have recently bought and sold shares of EW. Vanguard Group Inc. lifted its position in shares of Edwards Lifesciences by 2.0% in the 2nd quarter. Vanguard Group Inc. now owns 20,748,569 shares of the medical research company’s stock worth $2,453,311,000 after purchasing an additional 406,901 shares during the period. BlackRock Inc. lifted its position in shares of Edwards Lifesciences by 0.8% in the 2nd quarter. BlackRock Inc. now owns 14,109,514 shares of the medical research company’s stock worth $1,668,309,000 after purchasing an additional 105,819 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Edwards Lifesciences by 161.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock worth $627,207,000 after purchasing an additional 3,277,726 shares during the period. Wells Fargo & Company MN lifted its position in shares of Edwards Lifesciences by 20.2% in the 3rd quarter. Wells Fargo & Company MN now owns 2,548,282 shares of the medical research company’s stock worth $278,553,000 after purchasing an additional 429,022 shares during the period. Finally, American Century Companies Inc. lifted its position in shares of Edwards Lifesciences by 7.0% in the 3rd quarter. American Century Companies Inc. now owns 2,224,010 shares of the medical research company’s stock worth $243,107,000 after purchasing an additional 144,701 shares during the period. 81.63% of the stock is currently owned by hedge funds and other institutional investors.

In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $100.93, for a total transaction of $3,320,597.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $116.45, for a total transaction of $617,185.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 139,580 shares of company stock worth $14,849,205. Insiders own 2.13% of the company’s stock.

Edwards Lifesciences declared that its Board of Directors has initiated a share buyback program on Thursday, December 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to reacquire shares of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/edwards-lifesciences-corporation-to-post-q4-2017-earnings-of-0-89-per-share-william-blair-forecasts-ew/1756609.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.